Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-6 HCV Infected Population from Singapore, Malaysia, Thailand, and Vietnam: Results from a Phase 3, Clinical Trial

被引：0

作者：

Lim, Seng Gee ^{[1
]}

Mohamed, Rosmawati ^{[2
]}

Le, Phuong ^{[3
]}

Tee, Hoi Poh ^{[4
]}

McNabb, Brian L. ^{[5
]}

Lu, Sophia ^{[6
]}

Lu, Julia ^{[7
]}

McNally, John ^{[5
]}

Brainard, Diana M. ^{[5
]}

Subramanian, Mani ^{[5
]}

Tan, Chee-Kiat ^{[8
]}

Tanwandee, Tawesak ^{[9
]}

Kinh Nguyen Van ^{[10
]}

Piratvisuth, Teerha ^{[11
]}

机构：

[1] Natl Univ Singapore Hosp, Div Gastroenterol & Hepatol, Singapore, Singapore

[2] Univ Malaya, Dept Med, Kuala Lumpur, Malaysia

[3] Peoples Hosp 115, Ho Chi Minh City, Vietnam

[4] Hosp Tengku Ampuan Afzan, Dept Med, Gastroenterol Unit, Jalan Tanah Putih, Kuantan, Malaysia

[5] Gilead Sci Inc, Clin Res, 353 Lakeside Dr, Foster City, CA 94404 USA

[6] Gilead Sci Inc, Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA

[7] Gilead Sci Inc, Virol, 353 Lakeside Dr, Foster City, CA 94404 USA

[8] Singapore Gen Hosp, Dept Gastroenterol & Hepatol, Singapore, Singapore

[9] Mahidol Univ, Siriraj Hosp, Dept Med, Div Gastroenterol, Bangkok, Thailand

[10] Natl Hosp Trop Dis, Hanoi, Vietnam

[11] Prince Songkla Univ, NKC Inst Gastroenterol & Hepatol, Hat Yai, Thailand

来源：

HEPATOLOGY | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1094

引用

页码：586A / 586A

页数：1

共 50 条

[1] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN A GENOTYPE 1-6 HCV INFECTED POPULATION FROM SINGAPORE, MALAYSIA, THAILAND, AND VIETNAM: RESULTS FROM A PHASE 3, CLINICAL TRIAL
Lim, Seng Gee
Mohamed, Rosmawati
Phuong Le
Tee, Hoi Poh
McNabb, Brian
Lu, Sofia
Lu, Julia
McNally, John
Brainard, Diana M.
Subramanian, G. Mani
Yip, Christina Sze Man
Huang, Hai Cheng
Tan, Chee Kiat
Tanwandee, Tawesak
Kinh Nguyen Van
Piratvisuth, Teerha
GUT, 2018, 67 : A100 - A100
[2] Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial
Wei, Lai
Xie, Qing
Huang, Yan
Wu, Shanming
Xu, Min
Tang, Hong
Cheng, Jun
Gao, Yanhang
Mou, Zhuangbo
Dou, Xiaoguang
Nan, Yuemin
Ning, Qin
Mao, Yimin
Stamm, Luisa
Lu, Sophia
Dvory-Sobol, Hadas
Mo, Hongmei
Brainard, Diana
Yang, Yongfeng
Wang, Guiqiang
Hu, Peng
Zhang, Lunli
Gao, Zhiliang
Lin, Feng
Shang, Jia
Gong, Guozhong
Li, Jun
Su, Minghua
Duan, Zhongping
Hou, Jinlin
Jia, Jidong
HEPATOLOGY, 2018, 68 : 379A - 379A
[3] Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial
Weiland, Ola
Zhdanov, Konstantin
Chulanov, Vladimir P.
McNabb, Brian L.
Lu, Sophia
Svarovskaia, Evguenia S.
McNally, John
Brainard, Diana M.
Subramanian, Mani
Abdurakhmanov, Dzhamal
Isakov, Vasily
HEPATOLOGY, 2017, 66 : 639A - 639A
[4] Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial
Wei, Lai
Xie, Qing
Hou, Jinlin
Tang, Hong
Ning, Qin
Cheng, Jun
Nan, Yuemin
Zhang, Lunli
Li, Jun
Jiang, Jianning
McNabb, Brian L.
Zhang, Fangqiu
Camus, Gregory
Mo, Hongmei
McNally, John
Brainard, Diana M.
Subramanian, Mani
Gong, Guozhong
Mou, Zhuangbo
Wu, Shanming
Wang, Qui-Qiang
Hu, Peng
Gao, Yanhang
Jia, Jidong
Duan, Zhongping
HEPATOLOGY, 2017, 66 : 642A - 642A
[5] Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
Landis, Charles S.
Sulkowski, Mark S.
Reau, Nancy
Lutchman, Glen A.
Vainorius, Monika
Welzel, Tania M.
Zeuzem, Stefan
Khalili, Mandana
Nelson, David R.
Lok, Anna S.
Fried, Michael W.
Terrault, Norah
HEPATOLOGY, 2017, 66 : 587A - 587A
[6] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR-BASED REGIMENS FOR THE TREATMENT OF HCV GENOTYPE 1-6: RESULTS OF THE HCV-TARGET COHORT
Zeuzem, Stefan
Sulkowski, Mark S.
Lim, Joseph K.
Morelli, Giuseppi
Khalili, Mandana
Brown, Robert S., Jr.
Ben-Ari, Ziv
Park, James S.
Reddy, K. Rajender
Shiffman, Mitchell L.
Dong, Meichen
Vainorius, Monika
Fried, Michael W.
Nelson, David R.
Terrault, Norah
HEPATOLOGY, 2019, 70 : 939A - 940A
[7] EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN GENOTYPE 3 AND 6 HCV PATIENTS IN EAST CHINA
Wang Donghui
Jiang, Suwen
Liu, Linsong
Fan, Lingyan
Hu, Airong
HEPATOLOGY, 2021, 74 : 589A - 590A
[8] Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1-6: results of the HCV-TARGET Study
Khalili, M.
Welzel, T. M.
Lim, J. K.
Lutchman, G. A.
Nelson, D. R.
Borg, B.
Lok, A. S.
Ramani, A.
Reau, N.
Vainorius, M.
Fried, M. W.
Landis, C. S.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S716 - S717
[9] Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
Ferret, M. B.
Pineda, J.
Panero, J. L. C.
Rodriguez, M.
Morillas, R. M.
Pascasio, J. M.
Rivero, A.
Mcnabb, B.
Zhang, G.
Camus, G.
Stamm, L.
Brainard, D.
Subramanian, M.
Carrion, J. A.
Andrade, R. J.
Amado, L. E. M.
Turnes, J.
Lens, S.
Casado, M.
Esteban, R.
JOURNAL OF HEPATOLOGY, 2018, 68 : S20 - S21
[10] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study
Jacobson, Ira M.
Asselah, Tarik
Nahass, Ronald
Bhandari, Bal R.
Tran, Albert
Hyland, Robert H.
Stamm, Luisa M.
Dvory-Sobol, Hadas
Zhu, Yanni
Brainard, Diana M.
Subramanian, Mani
McHutchison, John G.
Shafran, Stephen
Davis, Mitchell
Stedman, Catherine A.
Lawitz, Eric
Gane, Edward J.
HEPATOLOGY, 2016, 64 (06) : 1126A - 1126A

← 1 2 3 4 5 →